Considering Recombinant-GH as treatment in to 8 pediatric patients with stable chronic heart failure secondary to dilated cardiomyopathy (DCM), McElhinney and the other authors determined several notable cardiovascular effects, including a trend toward improved LV ejection fraction during the course of GH treatment and significantly improved LV SF, SF z score, and LV end systolic stress z score 6 months after discontinuation of GH treatment (relative to baseline values) [41]. The gene discussed is GH1; the disease is familial dilated cardiomyopathy.